Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ernexa Therapeutics (ERNA) Total Current Liabilities (2016 - 2025)

Historic Total Current Liabilities for Ernexa Therapeutics (ERNA) over the last 16 years, with Q3 2025 value amounting to $2.1 million.

  • Ernexa Therapeutics' Total Current Liabilities fell 7845.66% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 7845.66%. This contributed to the annual value of $2.9 million for FY2024, which is 5530.2% down from last year.
  • Latest data reveals that Ernexa Therapeutics reported Total Current Liabilities of $2.1 million as of Q3 2025, which was down 7845.66% from $2.7 million recorded in Q2 2025.
  • In the past 5 years, Ernexa Therapeutics' Total Current Liabilities ranged from a high of $10.4 million in Q1 2025 and a low of $2.1 million during Q3 2025
  • Moreover, its 5-year median value for Total Current Liabilities was $7.1 million (2022), whereas its average is $6.5 million.
  • As far as peak fluctuations go, Ernexa Therapeutics' Total Current Liabilities soared by 6373.06% in 2022, and later crashed by 7845.66% in 2025.
  • Quarter analysis of 5 years shows Ernexa Therapeutics' Total Current Liabilities stood at $4.6 million in 2021, then skyrocketed by 67.83% to $7.7 million in 2022, then fell by 14.12% to $6.6 million in 2023, then tumbled by 55.3% to $2.9 million in 2024, then dropped by 27.03% to $2.1 million in 2025.
  • Its Total Current Liabilities was $2.1 million in Q3 2025, compared to $2.7 million in Q2 2025 and $10.4 million in Q1 2025.